Introduction
============

Meeting the requirement of real-time diagnosis, luminescence imaging recently became the research hotspot[@B1]. With fascinating and unique properties, rare earth elements have a great reputation in this domain, which lead to the wide and deep exploration in lanthanide doped nanomaterials to develop high efficient agents for luminescence imaging[@B2],[@B3]. Since biological tissues has an \"optical transparency window\" in near-infrared second window (NIR II) region, NIR II luminescence imaging take the advantage of deep tissue penetration, reduced photo-damage effects, low photo-scatting, and high signal-to-noise ratio in turn[@B4]-[@B6]. Recently, a brilliant strategy was come up, applying neodymium (Nd) as novel sensitizer which can be excited by 808 nm laser and emitted in NIR II region[@B7],[@B8]. Thanks to the long excitation and emission wavelength, Nd doped nanomaterials as NIR II downconversion luminescent (DCL) agents have the potential application in accurate real-time cancer diagnosis.

However, many works pointed out that luminescence imaging still have limitation in low tissue resolution[@B9],[@B10]. Thence, developing multifunctional luminescence agents coupled with high resolution imaging should be considered as priority. Among the imaging methods, T~2~-weighted magnetic resonance imaging (MRI) is widely used in clinical cancer diagnosis and can provide high resolution 3D images of pathological phenomena such as tumors and inflammation[@B11],[@B12]. Previous works suggested dysprosium (Dy) doped agents can be applied for effective T~2~-weighted MRI *in vitro* and *in vivo*[@B13]-[@B15]. For cancer ablation following comprehensive diagnosis, photothermal therapy (PTT) is also a novel targeted and non-invasive therapeutic intervention for cancer treatment, which can be easily achieved by the combination of photothermal conversion agents and suitable irradiation in the cancerous area, thereby killing ordinary tumor cells at a relative high temperature (\> 42°C)[@B16],[@B17]. Among all the discovered photothermal conversion agents, mainly including noble metals[@B18]-[@B20], semiconductors[@B21]-[@B24], molecular dyes[@B25]-[@B27], conjugated polymers[@B28]-[@B31], and carbon-based materials[@B32]-[@B34], the molecular dyes constitute the largest and most diverse family, which provide they with special performance in nanomaterial-based PTT[@B35]. Therefore, it is necessary to explore multifunctional nanoagents with outstanding NIR II DCL imaging and T~2~-weighted MRI properties, as well as photothermal therapeutic effect for cancer theranostic.

Apart from multifunction, the ultra-small hydrodiameter (sub 10 nm) was also required to avoid the accumulation in reticuloendothelial system, partly contributing to the long circulation time, high tumor accumulation amount, thus resulting in cancer theranostic improvement[@B36],[@B37]. However, the theranostic effect was still limited due to the small size. Therefore, a strategy for theranostic properties improvement of the accumulated nanoagents in tumor region was needed to be put forward. Considering the fact that rare earth based luminescence, T~2~-weighted MRI, and photothermal conversion properties were size dependent, developing a multifunctional nanoagent which can *in situ* aggregate in tumor region would seem to be a reasonable strategy for the cancer theranostic enhancement[@B38]-[@B40]. Since the tumor region was more acidic than normal tissues, the pH-induced *in situ* aggregation of the nanoagent in tumor region by aid of pH sensitive ligands was feasible for highly cancer theranostic enhancement.

In this work, we firstly reported a series of multifunctional NaDyF~4~ nanoagents doped with different amount Nd for NIR II DCL imaging and T~2~-weighted MRI, further discussing and optimizing their imaging properties. The optimized agent was then modified with photothermal conversion and pH-responsive gallic acid-Fe(III) complex (GA-Fe) and tested their pH induced theranostic properties enhancement. Following efforts have been directed towards treatment of tumor bearing-mice with the optimized GA-Fe modified nanoagents to illustrate their *in situ* aggregation-mediated enhanced theranostic effect and biosafety *in vitro* and *in vivo* (Scheme [1](#SC1){ref-type="fig"}).

Results and Discussion
======================

Synthesis and characterization of NaDyF~4~:x%Nd
-----------------------------------------------

Hydrophobic oleic acid (OA) coated NaDyF~4~:x%Nd (x = 2.5, 5, 10, 20) nanoagents were synthesized *via* a typical solvothermal method[@B15]. Transmission electron microscopy (TEM) images showed that the NaDyF~4~:x%Nd nanoagents are well dispersed in cyclohexane with good crystality and uniform shape (Figure [1](#F1){ref-type="fig"}A-D). All samples exhibit a narrow size distribution (6.6 ± 1.3 nm). The unobvious size change through Nd dopant may be interpreted to the low dopant amount and ultra-small size. The energy-dispersive X-ray analysis (EDXA) spectra and ICP-MS of the NaDyF~4~ nanoagents confirmed the exclusive composation of Na, Dy, and F (Figure [S1](#SM0){ref-type="supplementary-material"} and Table [S1](#SM0){ref-type="supplementary-material"}), which indicated the element formation of Nd doped NaDyF~4~ nanoagents. High-resolution TEM (HR-TEM) images and powder X-ray diffraction (XRD) patterns of NaDyF~4~:x%Nd nanoagents showed good crystallinity and confirmed their hexanol phase (JCPDS: 027-0687 for NaDyF~4~ and JCPDS: 35-1367 for NaNdF~4~) (Figure [S2](#SM0){ref-type="supplementary-material"}). Selected area electron diffraction (SAED) pattern could also support this observation (Figure [S3](#SM0){ref-type="supplementary-material"}).

Optimization of pH-responsive multifunctional nanoagents
--------------------------------------------------------

### Multifunctional imaging properties optimization

To obtain the hydrophilic NaDyF~4~:x%Nd for further application, nanoagents were treated using nitrosoniumtetrafluoroborate (NOBF~4~) to remove OA ligands on the surface, and gallic acid (GA) was then used to coat the four types of ligand-free nanoagents. Fourier transform infrared (FTIR) spectra proved the successful ligand exchange (Figure [S4](#SM0){ref-type="supplementary-material"}). Zeta potential investigation and dynamic light scattering (DLS) measurement suggested that all the four type nanoagents can well dispersed in water with a similar average hydrodiameter (HD) (Figure [1](#F1){ref-type="fig"}E).

The water-dispersible NaDyF~4~:x%Nd nanoagents were then investigated for positive longitudinal relaxivity (r~1~) and negative transverse relaxivity (r~2~) measurements, which were measured as a function of nanoagents molar concentrations at room temperature using a 3 T magnetic resonance imaging (MRI) system. All NaDyF~4~:x%Nd nanoagents showed good r~2~ enhancement and relative low r~1~ as a result of the presence of the Dy^3+^ ions (Figure [1](#F1){ref-type="fig"}F and Figure [S5](#SM0){ref-type="supplementary-material"}). As the Nd^3+^ dopant amount increasing, r~2~/r~1~ of NaDyF~4~:x%Nd decreased monotonously and surprisingly showed a linear relationship (Figure [S6](#SM0){ref-type="supplementary-material"}). Then, the near-infrared second window downconversion luminescence (NIR II DCL) was also taken into comparison. The NIR II DCL emission can be ascribed to the f-f electronic transition of Nd^3+^. Upon 808 nm excitation, DCL emission peaks of Nd in the NIR II region occurred at 1050 nm and 1330 nm, which correspond to the transition from ^4^F~3/2~ → ^4^I~11/2~ and ^4^F~3/2~ → ^4^I~13/2~. (Figure [1](#F1){ref-type="fig"}G and Figure [S7](#SM0){ref-type="supplementary-material"}). The interplay between both Nd concentration-induced absorption increment and concentration-induced luminescence quenching result in the max NIR emission peak at 10% Nd dopant amount. Nevertheless, with continuous increasing of Nd doping amount (\>13%), the cross-relaxation would lead to the luminescence quenching accordingly. NaDyF~4~:10%Nd has a similar quantum field of \~19.4% with previous work (\~22% for NaGdF~4~:3%Nd) and the different optimized Nd concentration may be contributed to the various hosts, which influenced the surrounding of Nd and their optical properties by crystal field[@B41]. Since the luminescence intensity at 1050 nm was much more stronger than that at 1330 nm, we then chose the 1050 nm luminescence for further study and imaging application. Considering all the factors above, NaDyF~4~:10%Nd among the four nanoagents has a preferable MR and NIR II DCL imaging effect, which can be optimized for the further study (Figure [1](#F1){ref-type="fig"}H).

### pH-responsive aggregation and properties enhancement

Gallic acid-Fe(III) complex (GA-Fe) has strong absorption at the range of 500-700 nm, and shows pH-responsive properties which can be efficiently aggregated in acidic condition (tumor region). The aggregation property of nanoagents may contribute to the protonation of modified GA-Fe(III) and the formation of hydrogen bond between oxygen atoms in hydroxyl groups and carboxyl groups according to previous report[@B42]. Hence, GA-Fe modified optimized NaDyF~4~:10%Nd nanoagents (NaDyF~4~:10%Nd-GA-Fe) can be expected to be photothermal agents and enhance cancer theranostic effect.

First, the NaDyF~4~:10%Nd-GA-Fe was synthesized and characterized (Figure [S8](#SM0){ref-type="supplementary-material"},9). Due to the separation of GA-Fe absorption wavelength (500-700 nm) and NaDyF~4~:10%Nd emission wavelength (1050 ± 25 nm), the GA-Fe modification has no obvious re-absorption effect on NIR II DCL of NaDyF~4~:10%Nd, which can ensure the efficiency of DCL imaging (Figure [S9](#SM0){ref-type="supplementary-material"}). The NaDyF~4~:10%Nd-GA-Fe can be well dispersed with a small hydrodiameter of 8.7 ± 0.9 nm and zeta potential of -28.47 mV. It also shows a similar absorption as reported free GA-Fe complex (Figure [S10](#SM0){ref-type="supplementary-material"}). Then, we studied the aggregation and enhancement effect under different pH condition (pH = 4.5-7.5). TEM and DLS analysis showed an increasing of the average size of NaDyF~4~:10%Nd-GA-Fe from 6.5 ± 0.7 nm (HD: 8.7 ± 0.9 nm) to 50.4 ± 4.4 nm (HD: 59.3 ± 6.6 nm) in acidic condition (pH = 4.5) and no obvious aggregation was observed in neutral condition (pH = 7.5) within 30 min (Figure [2](#F2){ref-type="fig"}A, B, D, E). Besides, relative high concentration of NaDyF~4~:10%Nd-GA-Fe showed more rapid aggregation than low concentration, which can be explained as the easy attachment of nanoparticles in high concentration solution (Figure [2](#F2){ref-type="fig"}F). These results suggest that NaDyF~4~:10%Nd-GA-Fe can efficiently aggregate under acidic condition. Notably, the aggregation-decomposition progress can be repeated by changing the pH condition (Figure [2](#F2){ref-type="fig"}C). After five circle of aggregation-decomposition progress, NaDyF~4~:10%Nd-GA-Fe can still show good solubility and small HD (\<10 nm) in solution (Figure [2](#F2){ref-type="fig"}G).

Besides, the ultraviolet-visible-near infrared (UV-vis-NIR) spectra also provide the same consequence by an obvious increase of absorption in low pH condition (Figure [3](#F3){ref-type="fig"}A). Because the aggregation of nanoagents increase the average size and further increase the molar extinction coefficient (ε value), the photothermal conversion effect of NaDyF~4~:10%Nd-GA-Fe under different pH condition was calculated using the following equation.

According to equation 1 and equation S1, the ε value of NaDyF~4~:10%Nd-GA-Fe was increasing from 1.89×10^6^ to 1.37×10^8^ M^-1^ cm^-1^ with the pH decreasing from 7.5 to 4.5, monotonously. The photothermal conversion efficiency (η value) of NaDyF~4~:10%Nd-GA-Fe (200 μg mL^-1^) under the pH = 4.5 condition was calculated using the following equation.

According to equation 2 and equation S2, the η value of the NaDyF~4~:10%Nd-GA-Fe is 60.12%, which is much higher than that of recently reported photothermal coupling agents (47.83% for rGO-Bi~2~S~3~, 36.10% for SnS) (Figure [S11](#SM0){ref-type="supplementary-material"})[@B43],[@B44]. Moreover, the enhancement of diagnosis signals was also studied. With the condition turned from neutral to acidic, the T~2~-weighted MRI and NIR II DCL signal intensity can be efficiently increased, which proved that NaDyF~4~:10%Nd-GA-Fe can be used for enhanced cancer theranostic (Figure [3](#F3){ref-type="fig"}E-H). The increasing of MRI and NIR II DCL property may contribute to the decrease of surface area, which result in the weakening of spin-canting effect and surface quenching effect.

The stability of NaDyF~4~:10%Nd-GA-Fe was also investigated. UV-vis-NIR spectra and DLS of NaDyF~4~:10%Nd-GA-Fe after several days standing and after several hours irradiation were measured, and suggested great stability under neural condition and different biological solution (Figure [S12](#SM0){ref-type="supplementary-material"}, Table [S2](#SM0){ref-type="supplementary-material"}, S3). Inductively coupled plasma mass spectrometry (ICP-MS) results suggested that no noticeable Fe(III) and Dy (III) leaching from NaDyF~4~:10%Nd-GA-Fe after 60 days standing or 1 hour irradiation in both neural and acidic condition. It was also found that NaDyF~4~:10%Nd-GA-Fe was a robust photothermal heater after five cycles of NIR laser-induced heating (Figure [3](#F3){ref-type="fig"}D). In all, the pH-responsive enhanced multifunctional properties and stability of NaDyF~4~:10%Nd-GA-Fe nanocomposites make them superior as a promising pH-responsive multifunctional agent for enhanced cancer theranostic.

### Power density optimization

Since the body temperature of human beings was \~37^o^C and the temperature over 42^o^C may increase the potential risk of overheat to normal tissues, temperature change less than 5^o^C will provide a safe condition for cancer diagnosis. To avoid the potential damage to normal tissues during the cancer diagnosis and obtain a high photothermal temperature change during the cancer therapy, the power density of irradiation laser was also optimized (Figure [3](#F3){ref-type="fig"}B, C). When the power density was 0.25 W cm^-2^ or lower, there are no obvious temperature increase (\<3^o^C), and thus NIR II DCL imaging can be performed under this power density stage (Figure [3](#F3){ref-type="fig"}B i). More importantly, the temperature change was lower than 5^o^C under 0.25-0.44 W cm^-2^ and can show a significant difference between acidic condition and neural condition. Hence, the power intensity range guarantees the safety of photothermal imaging (Figure [3](#F3){ref-type="fig"}I ii). While the power intensity increased to the range of 0.44-0.74 W cm^-2^, the temperature can increase by over 5^o^C in acidic condition and only by less than 5^o^C in neural condition, which suggested that the suitable laser power intensity range can both ensure the therapeutic effect and reduce the heat threaten to normal tissue (Figure [3](#F3){ref-type="fig"}B iii). Under the power intensity \>0.74 W cm^-2^, the temperature change can achieved over 5^o^C in both the acidic and neural condition, which may cause potential damage risk and hence not suitable for photothermal therapy (PTT) (Figure [3](#F3){ref-type="fig"}B iv). The low temperature change would lead to cell death, but the surviving cells would have the capacity to resistant further heat damage by activating the heat-shock proteins. Meanwhile, the high temperature can result in irreversible injury, by accelerating biological reaction and biomelecule damage. Therefore, the nanoagents would show high cytotoxicity under acidic condition rather than neutral condition. This result suggested that the using of 808 nm laser with different power density can both ensure the cancer diagnosis safety and the theranostic effect.

Cancer theranostic enhancement *in vitro* and *in vivo*
-------------------------------------------------------

T~2~-weighted MR image can reveal pathological phenomena and high-resolution 3D images, which would be benefit to the location of tumor[@B11]. Luminescence imaging achieves dynamic real-time imaging to monitor the ablation of tumor and photothermal images are used to record the real-time temperature change[@B45],[@B46]. Therefore, the combination of imaging modalities can provide complementary information in cancer theranostic. To confirm the potential application of NaDyF~4~:10%Nd-GA-Fe as a multifunctional imaging probe and show enhanced imaging effect in tumor region than normal tissue, a series of *in vitro* and *in vivo* experiments were carried out. A typical non-pH-responsive citric acid-Fe (III) complex modified NaDyF~4~:10%Nd (NaDyF~4~:10%Nd-CA-Fe, HD: 9.1 nm, zeta potential: -27.60 mV) with similar imaging properties was designed and optimized for comparison (Figure [S13](#SM0){ref-type="supplementary-material"}).

To demonstrate the feasibility of NaDyF~4~:10%Nd-GA-Fe as an enhanced multimodal imaging probe, we firstly compared the T~2~-weighted MRI *in vitro*. In comparison with in neutral condition, NaDyF~4~:10%Nd-GA-Fe in acidic condition showed a sharper contrast and NaDyF~4~:10%Nd-CA-Fe showed no obvious difference between those two conditions (Figure [4](#F4){ref-type="fig"}A). Further study was taken on HCT116 tumor-bearing mice model. Post-injection T~2~-weighted MRI images at 0 and 120 min showed clearly contrast in the tumor region, which illustrated the possibility as a T~2~-weighted MRI contrast agent for bioapplication (Figure [4](#F4){ref-type="fig"}B). Besides, T~2~-weighted MRI signals in tumor and liver region were measured 1 hour post-injection and the tumor/liver ratio from the MRI images were also calculated. The result suggested that mice receiving NaDyF~4~:10%Nd-GA-Fe had much more obvious tumor/liver ratio change than NaDyF~4~:10%Nd-CA-Fe (Figure [S14](#SM0){ref-type="supplementary-material"}). To further demonstrate the pH-induced T~2~-weighted MRI enhancement *in vivo*, nanoagents was intratumorally (2 mg per kg body weight of mouse) injected to tumor-bearing mice, respectively. By intratumorous injection, mice receiving NaDyF~4~:10%Nd-GA-Fe showed much more significant T~2~-weighted MRI signal enhancement in tumor region than that receiving NaDyF~4~:10%Nd-CA-Fe (Figure [4](#F4){ref-type="fig"}C). The same result was also found in NIR II DCL imaging (Figure [4](#F4){ref-type="fig"}D,E and Figure [S15](#SM0){ref-type="supplementary-material"}). The above results suggested that NaDyF~4~:10%Nd-GA-Fe can selectively enhanced the MRI and NIR II DCL signal in tumor region due to the acidic microenvironment*,* which illustrated the pH-responsive enhanced cancer diagnosis by *in situ* aggregation progress*in vivo* (Figure [S16](#SM0){ref-type="supplementary-material"}).

Since NaDyF~4~:10%Nd-GA-Fe possessed good solubility, stability, and photothermal conversion efficiency in biological aqueous media, it could be also considered as a photothermal therapeutic agent. NaDyF~4~:10%Nd-GA-Fe under the laser irradiation with an optimized power intensity of 0.64 W cm^-2^ showed enhanced photothermal therapeutic effect on cancerous cells (cell viability: \<10%) compared to normal cells (cell viability: \>75%) (Figure [4](#F4){ref-type="fig"}F). Considering the fact that NaDyF~4~:10%Nd-GA-Fe has enhanced photothermal therapeutic effect in tumor cells and the thermal signal of tumors increased over time and showed an obvious contradistinction with surrounding tissue after NaDyF~4~:10%Nd-GA-Fe injection (Figure [4](#F4){ref-type="fig"}G), PTT *in vivo* was further studied with several groups of HCT116 tumor-bearing mice. In the test group, mice were intravenously injected with a PBS solution of NaDyF~4~:10%Nd-GA-Fe and irradiated by a 808 nm continuous laser (Material + Laser, n = 5). For comparison, mice without injection of NaDyF~4~:10%Nd-GA-Fe (Laser, n = 5), without laser irradiation (Materials, n = 5), and without injection or laser irradiation were chosen as the control groups. Upon irradiation at 808 nm (0.64 W cm^-2^) for 6 min, the tumors of the test groups shrank within 9 days. After 11 days therapy period, the tumors were eliminated, with residual black scars and no obvious swollen parts, and the relative tumor volume (V/V~0~) shrank to 0. In contrast, the V/V~0~ of tumors in the control and blank groups showed rapid growth over time (Figure [4](#F4){ref-type="fig"}H). Besides, the bodyweight of mice were also determined. Within the first 3 days, the mice in test group showed a decrease in bodyweight, which demonstrated the efficient ablation of tumor by PTT. However, their bodyweight increase rapidly in the following 11 days, suggesting that the mice receiving PTT were in the recovery process from therapy and make a supplementary to the low toxicity of nanoagents (Figure [S17](#SM0){ref-type="supplementary-material"}).

The tissue distribution of both NaDyF~4~:10%Nd-GA-Fe and NaDyF~4~:10%Nd-CA-Fe was also quantificationally analyzed by ICP-MS and the Dy^3+^ is an indicator of the nanoagents which are not directly measured. Figure [4](#F4){ref-type="fig"}I shows that high dose of Dy^3+^ were uptake in both tumor region. These results demonstrated that the nanoagents can passive target and accumulate in the tumor region. More importantly, both of the nanoagents have a similar distribution in mice within 1 hour post-injection, indicating the cancer theranostic enhancement of NaDyF~4~:10%Nd-GA-Fe in tumor-bearing mice model based on their pH responsive properties. Besides, the relatively long blood circulation half-live time was determined to be \~56 min benefit from their ultra-small HD. Thence, to sum up the points which we have just indicated, the NaDyF~4~:10%Nd-GA-Fe can be applied to enhance cancer theranostic *in vitro* and *in vivo*.

Toxicity study
--------------

We then studied the *in vivo* toxicity of NaDyF~4~:10%Nd-GA-Fe to determine the safety of bioapplication. A MTT assay shows no significant difference in proliferation of both HCT116 and CCC-HEL-1 cells in the absence or presence of NaDyF~4~:10%Nd-GA-Fe (0-1.0 mg mL^-1^) within 24 and 48 hours (Figure [5](#F5){ref-type="fig"}A,B). Cellular viabilities were estimated to over 85% even at high dose. The half maximal (50%) inhibitory concentration (IC50) was also investigated *via* the MTT assay, and was calculated to be 3.97 mg mL^-1^ (24 hours) and 3.19 mg mL^-1^ (48 hours) for HCT116 cells, 3.94 mg mL^-1^ (24 hours) and 3.42 mg mL^-1^ (48 hours) for CCC-HEL-1 cells (Figure [S18](#SM0){ref-type="supplementary-material"}). The oxidation stress to HCT116 and CCC-HEL-1 cells was also determined by fluorescence method using singlet oxygen sensor green (SOSG). The result showed no obvious reactive oxygen species accumulation in both NaDyF~4~:10%Nd-GA-Fe incubated HCT116 and CCC-HEL-1 cells, which suggested low oxidation stress of NaDyF~4~:10%Nd-GA-Fe to cells (Figure [S19](#SM0){ref-type="supplementary-material"}). Moreover, healthy mice were injected intravenously with NaDyF~4~:10%Nd-GA-Fe at the dose of 20 mg per kg body weight of mouse. Neither mouse death nor noticeable abnormal behavior was observed. Serum biochemistry assays and complete blood panel tests were carried out on NaDyF~4~:10%Nd-GA-Fe-injected mice at 24 hours, 7 days, 30 days, and 60 days. The liver and kidney function indices, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), albumin (ALB), total protein (TP), uric acid (UA) and creatinine (CREA) were all tested to be normal, which suggested no hepatic or kidney function influenced by NaDyF~4~:10%Nd-GA-Fe (Figure [5](#F5){ref-type="fig"}C-I). Besides, hematoxylin-eosi (H&E) stained tissues sections were also taken to testify histological examination, which suggested no appreciable adverse effect of NaDyF~4~:10%Nd-GA-Fe to examined major organs, including liver, spleen, kidney, lung, and heart at 24 hours, 7 days, 30 days, and 60 days post-injection (Figure [5](#F5){ref-type="fig"}J). Dy amount in urine and feces was also determined by ICP-MS to study their metabolic pathway. The results suggested that NaDyF~4~:10%Nd-GA-Fe can be rapidly metabolized by renal and fecal pathway (\>80% within 48 hours), which greatly ensured their biosafty (Figure [S20](#SM0){ref-type="supplementary-material"}). Our results indicated that NaDyF~4~:10%Nd-GA-Fe was nontoxic to mice at our tested dose.

Conclusions
===========

In this work, we reported four types of ultra-small Nd doped NaDyF~4~ nanoagents *via* typical solvothermal method. Considering their theranostic properties, NaDyF~4~:10%Nd was optimized for further GA-Fe modification. The obtained NaDyF~4~:10%Nd-Fe-GA exhibited high r~2~ (27.9 mM^-1^ s^-1^), strong NIR II DCL (1050 nm and 1330 nm), outstanding photothermal conversion efficiency (60.12%), and unobservable toxicity. More importantly, the effective pH-responsibility properties make the nanoagents aggregate in acidic condition. Moreover, the *in vitro* and *in vivo* studies showed enhanced contrast in tumor region, which demonstrated that ultra-small NaDyF~4~:10%Nd-Fe-GA has the potential to be applied in efficient cancer theranostic by pH-responsive *in situ* aggregation. Our results provided a novel optimization strategy of developing multifunctional nanoagents, as well as encouraged the further research in the subfield of cancer theranostic enhancement.

Experimental
============

Materials
---------

Rare-earth oxides Nd~2~O~3~ (99.99%) and Dy~2~O~3~ (99.9%) were purchased from Beijing Lansu Co. China. Sodium hydroxide (NaOH), hydrochloride (HCl), ethanol, cyclohexane, and dichloromethane were purchased from Beijing Chemical Reagent Company. Oleic acid (OA) was purchased from Aldrich. 1-Octadecene (ODE), ammonium fluoride (NH~4~F), and nitrosoniumtetrafluoroborate (NOBF~4~) were purchased from Alfa Aesar Chemical (Tianjing) Co. Ltd. Iron (III) chloride (FeCl~3~•6H~2~O) was purchased from Thermo Fisher Scientific (China) Co Ltd. Gallic acid (GA) was purchased from Energy Chemical (Shanghai) Co. Ltd. Rare earth chlorides (LnCl~3~, Ln: Nd, Dy) were prepared by dissolving the corresponding metal oxide in HCl solution at elevated temperature and then evaporating the water completely under reduced pressure. All other chemical reagents were of analytical grade and were used directly without further purification. Deionized (DI) water was used throughout.

Synthesis of the OA-coated NaDyF~4~:x%Nd (x = 2.5, 5, 10, 20)
-------------------------------------------------------------

In a typical experiment, a mixture of 1 mM LnCl~3~ (Ln: Nd, Dy), 6 mL OA, and 15 mL ODE were added into a 100 mL three-necked flask. Under the vacuum, the mixture was heated to 160^o^C to form a clear solution, and then cooled to room temperature. After the solution cooling down, NaOH (0.025 mmol, 0.1 g) and NH~4~F (0.04 mmol, 0.1481 g) were added into the flask directly and stirred for 30 min. The solution was slowly heated with gently stirred, degassed at 100^o^C, and then heated to 300^o^C and maintained for 1 h under the argon atmosphere. After the solution was cooled naturally, the nanoparticles were washed with ethanol/cyclohexane (1:1 v/v) several times and dispersed in cyclohexane[@B15].

Synthesis of the GA-coated NaDyF~4~:x%Nd (x = 2.5, 5, 10, 20)
-------------------------------------------------------------

Ligand-free NaDyF~4~:x%Nd (x = 2.5, 5, 10, 20) was obtained by a reported method[@B47]. In a typical experiment, 5 mL of dichloromethane solution of NOBF~4~ (0.01 M) was dropped into 5 mL of OA-coated NaDyF~4~:x%Nd (x = 2.5, 5, 10, 20) dispersion in hexane (∼5 mg mL^-1^) at room temperature. Then, the ligand-free NaDyF~4~:x%Nd (x = 2.5, 5, 10, 20) were washed with ethanol several times and dispersed in DI water. Ligand-free NaDyF~4~:x%Nd (x = 2.5, 5, 10, 20) were then dispersed in a saturated solution of GA as the host reagent, being ultrasonically treated for 10 min at room temperature. The resultant mixture was separated to obtain GA-coated NaDyF~4~:x%Nd (x = 2.5, 5, 10, 20) (NaDyF~4~:x%Nd-GA) *via* centrifugation and washed with DI water several times to remove the extra GA.

Synthesis of the NaDyF~4~:10%Nd-GA-Fe
-------------------------------------

NaDyF~4~:10%Nd-GA-Fe were fabricated by simply mixing 5 mL 1.0 mg mL^-1^ FeCl~3~ with 10 mL 1 mg mL^-1^ NaDyF~4~:10%Nd-GA suspension (pH = 7.4) at room temperature. After vigorous stirring for another 50 min, the resulting colloidal solution was centrifuged and washed with DI water for several times.

Photothermal properties measurement
-----------------------------------

Photothermal imaging system was designed as described in previously literature[@B48]. To investigate the photothermal effect, NaDyF~4~:x%Nd (x = 2.5, 5, 10, 20) and NaDyF~4~:10%Nd-GA-Fe suspensions (200 μg mL^-1^) were poured in specimen bottles (total volume of 2.0 mL), irradiated by continuous-wave diode NIR laser with a center wavelength of 808 nm and output power of 0-1.5 W cm^-2^ for 2 min or 6 min. The temperature was measured by a digital thermometer with a thermo couple probe every 0.133 s. The photothermal images of NaDyF~4~:x%Nd (x = 2.5, 5, 10, 20) and NaDyF~4~:10%Nd-GA-Fe in solution were obtained using FLIR E40 equipment running on FLIR tools systems.

*In vivo* NIR II DCL imaging
----------------------------

The mice were scanned before and after the administration of contrast agent. The mice were injected with the solution of NaDyF~4~:10%Nd-GA-Fe intravenously (10 mg per kg body weight of mouse) and applied to NIR II DCL imaging, which was performed with a modified DCL*in vivo* imaging system designed as described in previously literature[@B34]. *In vivo* NIR II DCL signals were collected at 1060 ± 12 nm. NaDyF~4~:10%Nd-CA-Fe was used for comparison.

Oxidation stress study
----------------------

Singlet oxygen sensor green reagent (SOSG) solution (5 mL, 0.1 mM; molecular probes) was added to the medium containing HCT116 cells, NaDyF~4~:10%Nd-GA-Fe incubated HCT116 cells, CCC-HEL-1 cells, and NaDyF~4~:10%Nd-GA-Fe incubated CCC-HEL-1 cells. The fluorescence intensity of SOSG was determined at 531 nm with an excitation wavelength of 488 nm. Fluorescent measurements were obtained using a fluorescence spectrophotometer (Hitachi F-7000).
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![**Characterizations and optimization of NaDyF~4~:x%Nd (x = 2.5, 5, 10, 20) nanoagents.** TEM images A-D) of hydrophobic NaDyF~4~:x%Nd (x = 2.5, 5, 10, 20) nanoagents (Insert: size distribution of NaDyF~4~:x%Nd). Hydrodiameter E), transversal relaxivity (r~2~) F), and NIR II DCL G) properties of hydrophilic NaDyF~4~:x%Nd (x = 2.5, 5, 10, 20) nanoagents. The properties variation H) as a function of Nd concentration in obtained nanoagents (HD: the abbreviation of hydrodiameter; NIR II DCL: the NIR II DCL intensity under 808 laser irradiation with power intensity of 4.5 W cm^-2^). These results confirmed the successful controlled synthesis of ultra-small hexagonal phase NaDyF~4~:x%Nd (x = 2.5, 5, 10, 20) nanoagents and demonstrated that the 10% Nd doped NaDyF~4~ was preferred for further modification and applications.](thnov07p4217g002){#F1}

![**pH-induced aggregation-decomposition progress of NaDyF~4~:10%Nd-GA-Fe.** A-C) TEM images of NaDyF~4~:10%Nd-GA-Fe in aggregation-decomposition progress. D,E) Hydrodiameter *vs* time plots of NaDyF~4~:10%Nd-GA-Fe under different pH condition. F) Hydrodiameter *vs* concentration and pH plots of NaDyF~4~:10%Nd-GA-Fe. G) Hydordiameter variations of NaDyF~4~:10%Nd-GA-Fe under the different pH condition for five cycles. These results suggested NaDyF~4~:10%Nd-GA-Fe can response to different pH condition and hence aggregate in acidic condition.](thnov07p4217g003){#F2}

![**pH-induced properties enhancement of NaDyF~4~:10%Nd-GA-Fe.** A) UV-vis-NIR spectra of NaDyF~4~:10%Nd-GA-Fe under different pH condition within 30 min (pH = 4.5, 5.5, 6.5, and 7.5). Insert: relative intensity at 808 nm. Photothermal temperature change B) and photothermal images C) of NaDyF~4~:10%Nd-GA-Fe under laser irradiation with different power intensity. D) Temperature variations of NaDyF~4~:10%Nd-GA-Fe (200 ppm) under the continuous irradiations of 808 nm laser for four cycles. E,F) Relative MR intensity *vs* time plots of NaDyF~4~:10%Nd-GA-Fe under different pH condition (Insert: MRI images in tube). G,H) Relative DCL intensity *vs* time plots of NaDyF~4~:10%Nd-GA-Fe under different pH condition (Insert: NIR II DCL images in tube). These results suggested NaDyF~4~:10%Nd-GA-Fe has enhanced properties in acidic condition and the potential to achieve enhanced cancer theranostic.](thnov07p4217g004){#F3}

![**Enhanced cancer theranostics effect of NaDyF~4~:10%Nd-GA-Fe *in vitro* and *in vivo*.** T~2~-weighted MRI images in pre- and post-incubated cells A) and tumor-bearing mice within 120 min post-injection B). C) T~2~-weighted MRI signal in tumor region after intratumorous injection of NaDyF~4~:10%Nd-GA-Fe. NIR II DCL images in pre- and post-incubated cells D) and tumor-bearing mice E). F) Photothermal therapy efficiency *in vitro*. G) Photothermal images in pre- and post-injection tumor-bearing mice. H) Tumor growth rates of test group (Material + Laser), control groups (Laser only, Materials only) and blank group (Blank). I) Tissue distribution of NaDyF~4~:10%Nd-GA-Fe within 1 and 4 hour post-injection intravenously. NaDyF~4~:10%Nd-CA-Fe was used for comparison (control in 4A and 4D). Statistical significance was determined from one-way t tests. Note.\*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001](thnov07p4217g005){#F4}

![**Toxicity of NaDyF~4~:10%Nd-GA-Fe *in vitro* and *in vivo*.** The viability of HCT116 A) and CCC-HEL-1 B) cells incubated with different concentrations NaDyF~4~:10%Nd-GA-Fe within 24 and 48 hours. Serum biochemistry results obtained from mice injected with NaDyF~4~:10%Nd-GA-Fe (20 mg kg^-1^) different time post-injection (24 hours, 7 days, 30 days, and 60 days) and mice receiving no injection (control). C) ALT (alanine aminotransferase); D) AST (aspartate amino transferase); E) TBIL, total bilirubin; F) ALB, albumin; G) TP, total protein; H) CREA, creatinine; I) UA, uric acid. J) H&E-stained tissue sections from mice injected with NaDyF~4~:10%Nd-GA-Fe (20 mg kg^-1^) different time post-injection (24 hours, 7 days, 30 days, and 60 days) and mice receiving no injection (control). Tissues were harvested from heart, liver, spleen, lung, and kidney.](thnov07p4217g006){#F5}
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